In the News

Discover how Sunrise Association Day Camps are transforming summer for children affected by cancer.

The findings will lead to more accurate diagnoses and, potentially, to better treatments.

Two brothers discuss their surprise at being diagnosed with Lynch syndrome.

MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer.

New drugs are being developed that target part of the process to make proteins.

If you've been treated for soft tissue sarcoma, a recurrence may be a big concern for you. Here's what MSK's sarcoma experts think you should know about the disease coming back.

Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future.

A new imaging approach could shorten the time needed to determine whether a brain tumor treatment is working.

A lesser-known immune cell is suddenly getting more attention in the field of cancer immunology.

Drug resistance is a formidable challenge in cancer treatment. A drug called enasidenib (Idhifa®) was approved by the US Food and Drug Administration last year for the treatment of people with a form of acute myeloid leukemia (AML) that’s driven by a mutation in the gene IDH2. About 15 percent of people with AML have this mutation. Research led by Memorial Sloan Kettering Cancer Center (MSK) reports that people who take enasidenib can develop resistance to it — in a way never seen before. Enasidenib works differently than most cancer drugs. Rather than killing leukemia cells, it turns them into normal blood cells. The discovery of this unique resistence may lead to more-precise treatments for people with AML in the future.